Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:31 PM
Ignite Modification Date: 2025-12-24 @ 4:31 PM
NCT ID: NCT03470766
Eligibility Criteria: Inclusion Criteria: 1. Adults over the age of 18 2. Onset of low back pain \> 12 months 3. Low back pain intensity \> 60 out of 100mm on pain visual analogue scale (VAS) 4. Presence of clear component of neuropathic pain based on a PainDETECT Questionnaire score of \>19 (we will monitor this inclusion criteria in the early stage of the trial and revise if necessary) 5. Degenerative disc disease confirmed by imaging or internal disc disruption as confirmed by discography 6. On stable pain medications, as determined by the Investigator, for at least 28 days prior to enrolling in this study and not change medication dosage without consulting Investigator 7. Legally able to provide informed consent 8. Able to comply with study-related requirements, procedures and visits Exclusion Criteria: 1. Had previous spinal surgery 2. Chronic widespread pain 3. Subject has an active implanted device, whether turned on or off (e.g. pacemaker, intrathecal pump, deep brain stimulator etc.) 4. A current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, rapidly progressive diabetic peripheral neuropathy, brain or spinal cord tumour, or severe/critical central or foraminal spinal stenosis 5. Mechanical spine instability detected by a clinician (validation by flexion/extension films of lumbar spine within the past 6 months showing 4 mm or more translational movement or excessive angular movement manifested by \>5 degrees segmental angular movement) e.g. any forms of spondylolisthesis 6. A medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator 7. Bleeding diathesis such as coagulopathy or thrombocytopenia 8. Immunocompromised and at an increased risk for infection 9. Systemic infection or local infection that would contraindicate SCS placement 10. Metastatic malignant disease or active local malignant disease 11. Pregnant (if female and sexually active, subject must be using a reliable form of contraception, be surgically sterile or be at least 2 years post-menopausal) 12. Active alcohol, marijuana, recreational or prescription drug abuse or dependence or unwilling to stop/reduce excessive inappropriate medication. 13. Evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome as determined by the Investigator 14. Concomitant participation in another clinical trial (surgery, device or drug)
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT03470766
Study Brief:
Protocol Section: NCT03470766